[Special Stock] HLB Hits Lower Limit Following News of FDA Rejection for Liver Cancer Drug
HLB, along with HLB Life Science, HLB Global, HLB Therapeutics, and HLB Pharmaceutical, all fell to their price limit.
At 9:12 a.m. on the 17th, HLB was trading at 67,100 won, down 29.96% from the previous day. The market capitalization decreased from 12.5 trillion won to 8.8 trillion won.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
On the same day, Jin Yang-gon, chairman of the HLB Group, announced via YouTube that the company received a CRL (Complete Response Letter) from the U.S. Food and Drug Administration (FDA) regarding its application for new drug approval for the combination therapy of its 'Riboceranib' and China's Hansoh Pharmaceutical's 'Camrelizumab' as a first-line treatment for liver cancer.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
